Index
Peptide monographs
68 entries. Filter by class or search by name, alias, or chemical classification.
| Name | Class | MW | Half-life | Category |
|---|---|---|---|---|
| 3X Blend (Tesa / Ipa / MGF) Tesamorelin + Ipamorelin + MGF 5/2.5/0.5 | GHRH + GH-secretagogue + mechano-growth factor blend | Tesamorelin 5196; Ipamorelin 712; MGF ≈ 2868 g/mol | Tesamorelin ≈ 26 min; Ipamorelin ≈ 2 h; MGF ≈ 5–7 min | Multi-Peptide Blends |
| 5-Amino-1MQ 5-amino-1-methylquinolinium | Small-molecule NNMT inhibitor (non-peptide) | 159.2 g/mol | Not formally characterised in humans | Longevity & Mitochondrial |
| AOD-9604 | hGH(177-191) C-terminal fragment | 1817.1 g/mol | Short (minutes, plasma) | Metabolic & Incretin |
| ARA-290 Cibinetide | Innate repair receptor agonist (EPO-derived peptide) | 1257.3 g/mol | ≈ 2 min (plasma), prolonged receptor effect | Healing & Tissue Repair |
| BPC-157 Body Protection Compound 157 · PL 14736 | Pentadecapeptide fragment of gastric BPC | 1419.5 g/mol | ≈ 30 min (plasma, preclinical) | Healing & Tissue Repair |
| Cagrilintide AM833 | Long-acting amylin analogue | ≈ 3950 g/mol | ≈ 7 days | Metabolic & Incretin |
| Cerebrolysin FPF-1070 | Porcine brain-derived neuropeptide preparation | Peptide fraction < 10 kDa | Variable by fraction | Cognitive & Neurotrophic |
| CJC-1295 DAC:GRF · Modified GRF (1-29) | GHRH analogue (with or without Drug Affinity Complex) | 3367.9 g/mol (with DAC) | ≈ 8 days (with DAC); ≈ 30 min (without) | Growth Hormone Secretagogues |
| CJC-1295 / Ipa 2X Blend (10mg / 10mg) CJC-1295 No-DAC + Ipamorelin 10/10 | GHRH analogue (no-DAC) + GH-secretagogue blend (high-dose) | CJC-1295 No-DAC 3367 g/mol; Ipamorelin 711.9 g/mol | CJC-1295 No-DAC ≈ 30 min; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| CJC-1295 / Ipa 2X Blend (5mg / 5mg) CJC-1295 No-DAC + Ipamorelin 5/5 · Mod-GRF(1-29) + Ipamorelin | GHRH analogue (no-DAC) + selective GH-secretagogue blend | CJC-1295 No-DAC 3367 g/mol; Ipamorelin 711.9 g/mol | CJC-1295 No-DAC ≈ 30 min; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| Davunetide NAP · AL-108 · CP201 | ADNP-derived microtubule-stabilising octapeptide | 824.9 g/mol | Short; intranasal delivery used in trials | Cognitive & Neurotrophic |
| Dihexa N-hexanoic-Tyr-Ile-(6) aminohexanoic amide · PNB-0408 | Angiotensin IV analogue (oligopeptide) | 473.6 g/mol | Oral bioavailability reported; pharmacokinetics in humans not published | Cognitive & Neurotrophic |
| DSIP Delta Sleep-Inducing Peptide | Nonapeptide neuromodulator | 848.8 g/mol | ≈ 7–15 min (plasma) | Cognitive & Neurotrophic |
| Epitalon Epithalon · Epithalamin tetrapeptide | Synthetic tetrapeptide | 390.35 g/mol | Short (minutes) | Longevity & Mitochondrial |
| Exenatide Byetta · Bydureon · Exendin-4 | Exendin-4 GLP-1 receptor agonist | 4186.6 g/mol | ≈ 2.4 h (immediate release) | Metabolic & Incretin |
| Follistatin-344 FS-344 · FST | Activin-binding glycoprotein (myostatin inhibitor) | ≈ 38 kDa | Minutes to a few hours (rapid clearance) | Growth Hormone Secretagogues |
| FOXO4-DRI FOXO4 D-retro-inverso peptide | Senolytic peptide (p53-FOXO4 interaction disruptor) | ≈ 5100 g/mol | Extended by D-amino-acid protease resistance | Longevity & Mitochondrial |
| GHK-Cu Copper Tripeptide-1 | Copper-binding tripeptide | 402.92 g/mol (complex) | Short (topical/local activity) | Healing & Tissue Repair |
| GHRP-2 Pralmorelin · KP-102 | Synthetic growth hormone-releasing hexapeptide | 817.0 g/mol | ≈ 30 min | Growth Hormone Secretagogues |
| GHRP-6 Growth Hormone Releasing Peptide-6 | Synthetic growth hormone-releasing hexapeptide | 873.0 g/mol | ≈ 20–30 min | Growth Hormone Secretagogues |
| GLOW Blend (GHK-Cu / BPC-157 / TB-500) GLOW 70 · GHK-Cu + BPC-157 + TB-500 50/10/10 | Skin & soft-tissue regenerative blend | GHK 340 g/mol (with Cu²⁺ ≈ 402); BPC-157 ≈ 1419; TB-500 ≈ 4960 g/mol | GHK-Cu minutes (rapid tissue uptake); BPC-157 ≈ 4 h; TB-500 ≈ 2–3 h | Multi-Peptide Blends |
| Glucagon | 29-amino-acid pancreatic peptide hormone | 3482.8 g/mol | ≈ 3–6 min (IV) | Metabolic & Incretin |
| Gonadorelin GnRH · LHRH · Factrel | Native gonadotropin-releasing hormone decapeptide | 1182.3 g/mol | ≈ 2–4 min | Reproductive & Neuroendocrine |
| Hexarelin | Synthetic GH-releasing hexapeptide (GHRP) | 887.05 g/mol | ≈ 70 min (IV) | Growth Hormone Secretagogues |
| Humanin HN · HNG (potent analogue) | Mitochondrial-derived peptide | 2687.2 g/mol | Short in plasma; analogues extended | Longevity & Mitochondrial |
| IGF-1 DES(1-3) DES(1-3) IGF-1 | Truncated IGF-1 analogue | 7371 g/mol | ≈ 20–30 min | Growth Hormone Secretagogues |
| IGF-1 LR3 Long-R3-IGF-1 | Modified recombinant insulin-like growth factor 1 | 9111 g/mol | ≈ 20–30 h (extended vs. native IGF-1) | Growth Hormone Secretagogues |
| Ipamorelin | Selective ghrelin/GHS-R1a agonist | 711.86 g/mol | ≈ 2 h | Growth Hormone Secretagogues |
| Kisspeptin-10 KP-10 · Metastin fragment 45-54 | KISS1-derived neuropeptide | 1302.5 g/mol | ≈ 4 min | Reproductive & Neuroendocrine |
| KLOW Blend (GHK-Cu / BPC-157 / TB-500 / KPV) KLOW 80 · GLOW + KPV | Regenerative + immune-modulating blend | Composite; KPV 342.4 g/mol | GHK-Cu minutes; BPC-157 ≈ 4 h; TB-500 ≈ 2–3 h; KPV short systemic | Multi-Peptide Blends |
| KPV α-MSH(11-13) | C-terminal tripeptide fragment of α-MSH | 342.4 g/mol | Short (minutes) | Immune & Thymic |
| Larazotide AT-1001 · Larazotide acetate | Tight-junction regulator (zonulin antagonist) | 726.8 g/mol | Minimal systemic absorption (acts luminally) | Healing & Tissue Repair |
| Liraglutide Victoza · Saxenda | Acylated GLP-1 receptor agonist | 3751.2 g/mol | ≈ 13 h | Metabolic & Incretin |
| LL-37 Cathelicidin · hCAP18 fragment | Cathelicidin antimicrobial peptide | 4493.3 g/mol | Short in plasma; locally active | Immune & Thymic |
| Mazdutide IBI362 · LY3305677 · OXM analogue | GLP-1 / glucagon (oxyntomodulin) dual agonist | ≈ 4300 g/mol | ≈ 5–6 days | Metabolic & Incretin |
| Melanotan-1 MT-1 · Afamelanotide | α-MSH analogue (melanocortin agonist) | 1646.8 g/mol | ≈ 30 min (free); sustained-release implant approved | Cognitive & Neurotrophic |
| Melanotan-2 MT-2 | Cyclic α-MSH analogue (non-selective melanocortin agonist) | 1024.2 g/mol | ≈ 33 min | Cognitive & Neurotrophic |
| MGF Mechano Growth Factor · IGF-1Ec | IGF-1 splice variant E-domain peptide | 2867 g/mol | Minutes (native form) | Growth Hormone Secretagogues |
| MK-677 Ibutamoren · L-163,191 | Non-peptide oral ghrelin receptor agonist | 528.7 g/mol | ≈ 4–6 h (once-daily dosing) | Growth Hormone Secretagogues |
| MOTS-c | Mitochondrial-derived peptide (MDP) | 2174.6 g/mol | Short (preclinical) | Longevity & Mitochondrial |
| NAD+ Nicotinamide Adenine Dinucleotide | Pyridine dinucleotide coenzyme (not a peptide) | 663.4 g/mol | Tissue-specific; intracellular pool turns over within hours | Longevity & Mitochondrial |
| Noopept GVS-111 · N-phenylacetyl-L-prolylglycine ethyl ester | Proline-containing dipeptide nootropic | 318.4 g/mol | ≈ 30–60 min (active metabolite cycloprolylglycine longer) | Cognitive & Neurotrophic |
| Oxytocin | Nonapeptide neuropeptide / hormone | 1007.2 g/mol | ≈ 1–6 min (IV); ≈ 20 min (intranasal CNS effects) | Cognitive & Neurotrophic |
| P21 P021 · Ciliary neurotrophic factor peptide mimetic | CNTF-derived neurogenic tetrapeptide | ≈ 530 g/mol | Not formally characterised in humans | Cognitive & Neurotrophic |
| PEG-MGF Pegylated Mechano Growth Factor | PEGylated IGF-1Ec E-domain peptide | ≈ 2867 g/mol plus PEG moiety | Hours to days (PEG-extended) | Growth Hormone Secretagogues |
| Pentadeca Arginate PDA · BPC-157 arginate salt · PDA-157 | Arginate-stabilised pentadecapeptide | ≈ 1419 g/mol (peptide portion) | Reported longer than acetate form; not formally characterised | Healing & Tissue Repair |
| Pinealon Glu-Asp-Arg · EDR peptide | Short bioregulator tripeptide (Khavinson peptide) | 418.4 g/mol | Minutes | Cognitive & Neurotrophic |
| Pramlintide Symlin · Amylin analogue | Synthetic amylin (IAPP) analogue | 3949.4 g/mol | ≈ 48 min | Metabolic & Incretin |
| PT-141 Bremelanotide | Melanocortin receptor agonist | 1025.2 g/mol | ≈ 2.7 h | Cognitive & Neurotrophic |
| Retatrutide LY3437943 · GLP-1/GIP/Glucagon triple agonist | Triple GLP-1 / GIP / Glucagon receptor agonist | ≈ 4900 g/mol | ≈ 6 days | Metabolic & Incretin |
| Selank | Synthetic tuftsin analogue | 751.9 g/mol | Short (minutes, intranasal) | Cognitive & Neurotrophic |
| Semaglutide | GLP-1 receptor agonist (incretin mimetic) | 4113.6 g/mol | ≈ 165 h (≈ 1 week) | Metabolic & Incretin |
| Semax | Synthetic ACTH(4-10) analogue | 813.9 g/mol | Short (minutes, intranasal); CNS effects persist hours | Cognitive & Neurotrophic |
| Sermorelin GHRH(1-29) · GRF 1-29 | GHRH(1-29) analogue | 3358 g/mol | ≈ 10–20 min (SC) | Growth Hormone Secretagogues |
| SS-31 Elamipretide · MTP-131 · Bendavia | Mitochondria-targeted tetrapeptide | 639.8 g/mol | ≈ 2–4 h (SC) | Longevity & Mitochondrial |
| Survodutide BI 456906 | Dual glucagon / GLP-1 receptor agonist | ≈ 4500 g/mol | ≈ 6 days | Metabolic & Incretin |
| TB-500 Thymosin Beta-4 fragment | Synthetic fragment of Thymosin β4 | ≈ 889 g/mol (fragment) | 2–3 h (preclinical) | Healing & Tissue Repair |
| Tesa/Ipa 2X Blend (12mg / 3mg) Tesamorelin + Ipamorelin 12/3 | GHRH-dominant + GH-secretagogue blend | Tesamorelin 5196 g/mol; Ipamorelin 711.9 g/mol | Tesamorelin ≈ 26 min; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| Tesa/Ipa 2X Blend (5mg / 5mg) Tesamorelin + Ipamorelin 5/5 | GHRH analogue + selective GH-secretagogue blend | Tesamorelin 5196 g/mol; Ipamorelin 711.9 g/mol | Tesamorelin ≈ 26 min systemic; Ipamorelin ≈ 2 h | Multi-Peptide Blends |
| Tesamorelin | Stabilized GHRH(1-44) analogue | 5135.9 g/mol | ≈ 26 min (SC) | Growth Hormone Secretagogues |
| Thymalin Thymus peptide extract · Timalin | Thymic polypeptide complex | Fractions < 10 kDa | Not formally characterised | Immune & Thymic |
| Thymosin α1 Tα1 · Thymalfasin | Thymic peptide | 3108.3 g/mol | ≈ 2 h (SC) | Immune & Thymic |
| Thymulin Facteur Thymique Sérique · FTS · Zinc-thymulin | Zinc-dependent thymic nonapeptide | 857.9 g/mol (plus Zn²⁺) | Short in plasma | Immune & Thymic |
| Tirzepatide | Dual GIP / GLP-1 receptor agonist | 4813.5 g/mol | ≈ 120 h (≈ 5 days) | Metabolic & Incretin |
| Triptorelin Decapeptyl · Trelstar · GnRH agonist | Long-acting GnRH receptor agonist | 1311.5 g/mol | ≈ 3 h (immediate release); depot forms far longer | Reproductive & Neuroendocrine |
| Ultratrutide Next-generation triple agonist | Multi-receptor incretin agonist (investigational) | ≈ 5000 g/mol (reported) | Weekly-dosing pharmacokinetics (reported) | Metabolic & Incretin |
| VIP Vasoactive Intestinal Peptide · Aviptadil | Secretin-family neuropeptide | 3325.8 g/mol | ≈ 1–2 min (native) | Immune & Thymic |
| Wolverine Blend (BPC-157 / TB-500) BPC-157 + TB-500 · Wolverine 20mg | Tissue-repair co-lyophilized blend | BPC-157 ≈ 1419 g/mol; TB-500 (fragment) ≈ 4960 g/mol | BPC-157 ≈ 4 h; TB-500 ≈ 2–3 h (parent fragment) | Multi-Peptide Blends |